Supportive-expressive group therapy for women with metastatic breast cancer: Survival and psychosocial outcome from a randomized controlled trial

David W Kissane, Brenda Grabsch, David Murray Clarke, Graeme Crawford Smith, Anthony W Love, Sidney Bloch, Raymond Snyder, Yuelin Li

Research output: Contribution to journalArticleResearchpeer-review

281 Citations (Scopus)


BACKGROUND: Mixed reports exist about the impact of supportive-expressive group therapy (SEGT) on survival. METHODS: From 485 women with advanced breast cancer recruited between 1996-2002, 227 (47 ) consented and were randomized within an average 10 months of cancer recurrence in a 2:1 ratio to intervention with 1 year or more of weekly SEGT plus three classes of relaxation therapy (147 women) or to control receiving three classes of relaxation therapy (80 women). The primary outcome was survival; psychosocial well-being was appraised secondarily. Analysis was by intention-to-treat. RESULTS: SEGT did not prolong survival (median survival 24.0 months in SEGT and 18.3 in controls; univariate hazard ratio for death 0.92 [95 CI, 0.69-1.26]; multivariate hazard ratio, 1.06 [95 CI, 0.74-1.51]). Significant predictors of survival were treatment with chemotherapy and hormone therapy (p
Original languageEnglish
Pages (from-to)277 - 286
Number of pages10
Issue number4
Publication statusPublished - 2007

Cite this